SynAct Pharma shareholders propose Marina Bozilenko as new board member
SynAct Pharma AB ("SynAct") today announced that shareholders representing more than 20 per cent of the shares and votes in the company propose Marina Bozilenko to be elected as new board member of SynAct Pharma at the next annual general meeting set for May 21, 2021.Marina Bozilenko has more than 30 years of experience in investment banking and the healthcare industry, including raising more than $30 billion in capital and executing numerous M&A transactions. Ms. Bozilenko currently serves as Strategic Advisor to William Blair & Company, a firm she joined in 2010 as Head of Biotech &